title: Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography.
abstract: Alterations in a variety of neurotransmitter systems have been identified in experimental models of epilepsy and in brain tissue from patients with intractable temporal lobe seizures. The availability of new high-affinity radioligands permits the study of some neuroreceptors in vivo with positron emission tomography (PET). We previously characterized the in vivo binding of 11C-carfentanil, a potent and selective mu opiate receptor agonist, and described increases in 11C-carfentanil binding in the temporal neocortex of patients with unilateral temporal lobe epilepsy. These studies have been extended to 11C-diprenorphine, which labels mu, kappa, and delta opiate receptor subtypes. Paired measurements of opiate receptor binding were performed with PET using 11C-carfentanil and 11C-diprenorphine in patients with unilateral temporal lobe seizures. Carfentanil binding, reflecting changes in mu opiate receptors, was increased in the temporal neocortex and decreased in the amygdala on the side of the epileptic focus. Diprenorphine binding, reflecting mu as well as non-mu opiate subtypes, was not significantly different among regions in the focus and nonfocus temporal lobes. Regional glucose metabolism, measured using 18F-2-fluoro-2-deoxyglucose, was decreased in the mesial and lateral aspects of the temporal lobe ipsilateral to the epileptogenic focus. The variation in pattern of carfentanil and diprenorphine binding supports a differential regulation of opiate subtypes in unilateral temporal lobe epilepsy.
authors.affiliation: Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
authors.forename: H S
authors.initials: HS
authors.lastname: Mayberg
authors.forename: B
authors.initials: B
authors.lastname: Sadzot
authors.forename: C C
authors.initials: CC
authors.lastname: Meltzer
authors.forename: R S
authors.initials: RS
authors.lastname: Fisher
authors.forename: R P
authors.initials: RP
authors.lastname: Lesser
authors.forename: R F
authors.initials: RF
authors.lastname: Dannals
authors.forename: J R
authors.initials: JR
authors.lastname: Lever
authors.forename: A A
authors.initials: AA
authors.lastname: Wilson
authors.forename: H T
authors.initials: HT
authors.lastname: Ravert
authors.forename: H N
authors.initials: HN
authors.lastname: Wagner
mesh_terms: D000679:Amygdala / Q000737:chemistry*; D003847:Deoxyglucose / Q000031:analogs & derivatives; D004174:Diprenorphine / Q000378:metabolism*; D004569:Electroencephalography; D004833:Epilepsy, Temporal Lobe / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D005283:Fentanyl / Q000031:analogs & derivatives* / Q000378:metabolism; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism; D006801:Humans; D008279:Magnetic Resonance Imaging; D011957:Receptors, Opioid / Q000032:analysis* / Q000378:metabolism; D017450:Receptors, Opioid, mu; D013702:Temporal Lobe / Q000737:chemistry*; D014055:Tomography, Emission-Computed
chemical_list: D011957:Receptors, Opioid; D017450:Receptors, Opioid, mu; D019788:Fluorodeoxyglucose F18; D004174:Diprenorphine; D003847:Deoxyglucose; D005947:Glucose; C017114:carfentanil; D005283:Fentanyl